Dergiler / Turkish Journal of Medical Sciences / 2014 / Cilt: 44 - Sayı: 2

The place of androgen receptor gene mutation analysis in the molecular diagnosis of prostate cancer and genotype–phenotype relationship

Sayfa
261–266
Yayın Tarihi
2014-05-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Randomized prospective studies should be planned with larger patient and control groups and with more variables, which may open new horizons in prostate cancer screening and early detection.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:To determine the relationship between androgen receptor (AR) gene polymorphism and prostate cancer in our society.
📊
Temel Bulgular & Veri:Materials and methods: Thirty-nine patients diagnosed with prostate cancer and 34 benign prostatic hyperplasia (BPH) patients who were diagnosed in 2010 met the study criteria.
💡
Sonuç & Katkı:Conclusion: Randomized prospective studies should be planned with larger patient and control groups and with more variables, which may open new horizons in prostate cancer screening and early detection.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2010 Verileri
⚙️Değişkenler:Key words: Androgen receptor · mutation · polymorphism

Özet

To determine the relationship between androgen receptor (AR) gene polymorphism and prostate cancer in our society. Materials and methods: Thirty-nine patients diagnosed with prostate cancer and 34 benign prostatic hyperplasia (BPH) patients who were diagnosed in 2010 met the study criteria. The inclusion criteria included patients whose diagnosis was confirmed with a biopsy, with the presence of adequate pathologic material for review, between the ages of 40 and 80, and who were healthy men without a family history of prostate cancer. The exclusion criteria excluded men diagnosed with another cancer and those who had kin with a history of prostate cancer. A direct DNA sequencing method was utilized for detection of polymorphisms. Results: CAG repeat length varied from 13 to 28 (mean: 21.67) for the BPH group and 12 to 28 (mean: 21.74) for the prostate cancer group. Prostate-specific antigen (PSA) density and the androgen receptor (AR) CAG repeat had a statistically significant negative correlation in the BPH group. A statistically significant difference was associated between AR CAG repeat and PSA density. Conclusion: Randomized prospective studies should be planned with larger patient and control groups and with more variables, which may open new horizons in prostate cancer screening and early detection.

Abstract

To determine the relationship between androgen receptor (AR) gene polymorphism and prostate cancer in our society. Materials and methods: Thirty-nine patients diagnosed with prostate cancer and 34 benign prostatic hyperplasia (BPH) patients who were diagnosed in 2010 met the study criteria. The inclusion criteria included patients whose diagnosis was confirmed with a biopsy, with the presence of adequate pathologic material for review, between the ages of 40 and 80, and who were healthy men without a family history of prostate cancer. The exclusion criteria excluded men diagnosed with another cancer and those who had kin with a history of prostate cancer. A direct DNA sequencing method was utilized for detection of polymorphisms. Results: CAG repeat length varied from 13 to 28 (mean: 21.67) for the BPH group and 12 to 28 (mean: 21.74) for the prostate cancer group. Prostate-specific antigen (PSA) density and the androgen receptor (AR) CAG repeat had a statistically significant negative correlation in the BPH group. A statistically significant difference was associated between AR CAG repeat and PSA density. Conclusion: Randomized prospective studies should be planned with larger patient and control groups and with more variables, which may open new horizons in prostate cancer screening and early detection.

🔖

Bu Makaleye Atıf Yap

KIZILAY, F., KALEMCİ, M. S., ŞİMŞİR, A., TURNA, B., NAZLI, O., BERDELİ, A. (2014). The place of androgen receptor gene mutation analysis in the molecular diagnosis of prostate cancer and genotype–phenotype relationship. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 2, 261–266. https://ajindex.com/articles/383239

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000; 92: 2009–2017.
  2. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999; 81: 672–676.
  3. Eeles RA, Edwards SM, Minter R. Androgen receptor polymorphisms: their association with prostate cancer risk, relapse and overall survival. Programs and abstracts of the 1998 Annual Meeting of the American Society of Human Genetics. Am J Hum Genet 1998; 4: A21. Chamberlain NC, Driver ED, Mielsfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucl Acid Res 1994; 22: 3181–3186.
  4. Kufe DW, Pollack RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, editors. Cancer Medicine. 6th ed. Hamilton, ON, Canada: B.C. Decker; 2003.
  5. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg 1998; 3: 9–15.
  6. Balic I, Graham ST, Troyer DA, Higgins BA, Pollock BH, Johnson-Pais TL, Thompson IM, Leach RJ. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 2002: 168: 2245–2248.
  7. Mononen N, Ikonen T, Autio V, Rökman A, Matikainen MP, Tammela TL, Kallioniemi OP, Koivisto PA, Schleutker J. Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet 2002; 111: 166–171.
  8. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002; 12: 182–196.
  9. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002; 155: 883–890.
  10. Lai CL, L’Eplattenier H, van den Ham R, Verseijden F, Jagtenberg A, Mol JA, Teske E. Androgen receptor CAG repeat polymorphisms in canine prostate cancer. J Vet Intern Med 2008; 22: 1380–1384.
  11. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan- Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 1130–1137.
  12. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, de La Rosette JJ. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benig